Amsbio Launches New StemFit Basic05 Culture Medium
The animal-free formulation supports both 2D and 3D stem cell cultures to streamline expansion and scale-up workflows.
Updated on Oct. 27, 2026 in Life Sciences
Live Poll
Do you believe advancements in lab technology will make future medical treatments more affordable for you?
Amsbio has launched StemFit Basic05, an animal origin-free culture medium designed for human pluripotent stem cells. This product supports both 2D and 3D culture systems while allowing researchers to maintain cell lines through expansion and scale-up using a single formulation.
Why it matters
The new medium aims to eliminate the need for costly redevelopment and process optimization often required when switching between different media types for stem cell growth. By enabling direct differentiation from 3D aggregates, it streamlines workflows for laboratories transitioning from small-scale research to larger production.
StemFit Basic05 supports flexible feeding schedules and consistent cell viability in both 2D adherent and 3D suspension culture systems. It preserves the capacity of human pluripotent stem cells to differentiate while maintaining a normal karyotype—the full set of chromosomes in a cell.
The players
Amsbio
A life sciences manufacturer providing specialized reagents and media for stem cell research and regenerative medicine.
The details
The medium functions as an animal origin-free solution, meaning it contains no components derived from animals, which reduces the risk of batch-to-batch variability. By supporting 3D aggregates—clusters of cells grown in suspension—the medium allows for uniform spheroid formation and process scale-up. This unified formulation prevents the need for medium swaps during the transition from expansion to differentiation.
Timeline
October 27, 2026: Amsbio launched the StemFit Basic05 culture medium.
The Tech Race
This release follows the industry trend toward unified media systems that support the transition from 2D adherent to 3D suspension stem cell culture systems. It directly competes in the growing market for specialized media that facilitate scalable, reliable manufacturing of pluripotent stem cells for therapeutic research.
Researchers working with human pluripotent stem cells can now adopt a single-formulation workflow for both expansion and scale-up, reducing optimization steps. Interested laboratories can contact Amsbio regional offices in the US at +1-617-945-5033, the UK at +44-1235-828200, or the Netherlands at +31-72-8080244 for availability.
The takeaway
The move toward single-formulation, animal-free media is reducing the technical overhead associated with scaling human stem cell production. Researchers should monitor subsequent validation studies for their specific cell lines to confirm performance consistency during high-density 3D cultivation.
Further reading
Explore more developments in biotechnology and cell research in our Life Sciences section.
Source note: This article includes information reported by Labmate online.
Live Poll
Do you believe advancements in lab technology will make future medical treatments more affordable for you?
